BioXtal, Speeding up your discoveries. From DNA to 3D structure.

Quick-off meeting of Synsignal: An EU FP7 7M€ funded consortium involving Bio-Xtal with 6 other partners will be dedicated to the development of synthetic pathway related to GPCR signaling.


BIO San Diego: Meet us in San Diego to the 2014 BIO International Convention


BioXtal as concluded a licencing Agreement with LifeTechnologies for the development of tetracycline inducible mammalian stable cell lines.


Bio-Xtal in association with the CEA is proposing a new expertise to develop scaffold free binders based on Stamps™ technology.

Artificial binder technology

The artificial binder technology has been developed by the CEA on the principal of a scaffold-free binder. Starting from a protein-protein complex structure, the technology identifies scaffolds from the PDB that present the same topological profil as the binding motif of a complexed partner. Once the appropriate scaffold is selected from the PDB, the binding motif of the initial protein is 'transferred' by mutating the new scaffold and tested for binding. Artificial binders have been successfully discovered using this technology for ion channel ligand mimetics and metalloprotease inhibitor mimetics.


Structure-based secondary structure-independent approach to design protein ligands: Application to the design of Kv1.2 potassium channel blockers.
Cuniasse P. et al.
J Am Chem Soc. 2006 Dec 20;128(50):16190-205.